^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr t(11;14)(q13;q32)

    1year
    MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR and ddPCR. (PubMed, Methods Mol Biol)
    However, it should be noted that MRD diagnostics for clinical treatment protocols has to be accompanied by regular international quality control rounds to ensure the reproducibility and reliability of the MRD results. This is available by the EuroMRD network ( https://euromrd.org ), a subgroup of ESHLO ( https://eslho.org ).
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus)
    |
    Chr t(11;14) • Chr t(11;14)(q13;q32) • BCL2 fusion
    1year
    Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14). (PubMed, Leukemia)
    Overexpression of PAX5 resulted in increased CCND1 expression. These results support the importance of rs9344 G enhancer in increasing CCND1 expression in MM.
    Journal
    |
    CCND1 (Cyclin D1) • PAX5 (Paired Box 5)
    |
    Chr t(11;14) • CCND1 overexpression • CCND1 expression • Chr t(11;14)(q13;q32) • PAX5 overexpression • CCND1-H
    1year
    Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 9
    Enrollment closed • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
    |
    CD20 positive • Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Imbruvica (ibrutinib) • Calquence (acalabrutinib)
    over1year
    Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=50 --> 32
    Enrollment closed • Enrollment change
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Venclexta (venetoclax) • Calquence (acalabrutinib)
    over1year
    CAPITAL: Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Jun 2024
    Trial completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Truqap (capivasertib)
    over1year
    Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV
    almost2years
    Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL (clinicaltrials.gov)
    P1/2, N=33, Recruiting, Han weidong | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • decitabine • fludarabine IV
    almost2years
    ALTAMIRA: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, Nordic Lymphoma Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Rituxan (rituximab) • Calquence (acalabrutinib)
    almost2years
    ACE-LY-004: An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=124, Active, not recruiting, Acerta Pharma BV | Trial completion date: Dec 2025 --> Sep 2026
    Trial completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Calquence (acalabrutinib)
    almost2years
    V-MIND: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=100, Recruiting, Academic and Community Cancer Research United | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    CD19 (CD19 Molecule) • CCND1 (Cyclin D1)
    |
    Chr t(11;14) • CCND1 overexpression • CD19 expression • Chr t(11;14)(q13;q32)
    |
    Venclexta (venetoclax) • lenalidomide • Monjuvi (tafasitamab-cxix)
    almost2years
    Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Venclexta (venetoclax) • Calquence (acalabrutinib)
    almost2years
    Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Venclexta (venetoclax) • Calquence (acalabrutinib)